Fierce Biotech March 4, 2024
Helen Floersh

The Department of Health and Human Services’ (HHS’) new biomedical research arm, the Advanced Research Projects Agency for Health (ARPA-H), is behind on finalizing a plan to avoid unnecessary research duplication with other government health agencies, despite already awarding funds.

ARPA-H was established by Congress in 2022 with the goal of translating public medical research conducted by agencies like the National Institutes of Health (NIH) into treatments and therapies developed by private companies in the pharmaceutical and biotech industry. In an FAQ, the agency describes the proposals funded by the NIH as “curiosity-driven,” while those funded by ARPA-H are “use-driven.”

It’s a fine line, and, according to a new report published Feb. 29 by the U.S. Government Accountability Office (GAO),...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, GAO, Govt Agencies, HHS, Pharma, Pharma / Biotech
Patient advocates shred Becerra's copay accumulator comments
Opinion: Former HHS secretaries: Congress should adopt site-neutral payments for health care
HHS finalizes rule on 340B Administrative Dispute Resolution process
No end to surprise-billing surprises
HHS secretary: Rural health would improve if states expand Medicaid

Share This Article